Abeer M Shaaban

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/375504/publications.pdf

Version: 2024-02-01

118 papers

2,751 citations

201658 27 h-index 206102 48 g-index

123 all docs

123 docs citations

times ranked

123

3614 citing authors

#	Article	IF	CITATIONS
1	Nuclear and Cytoplasmic Expression of $ER\hat{1}^2$ 1, $ER\hat{1}^2$ 2, and $ER\hat{1}^2$ 5 Identifies Distinct Prognostic Outcome for Breast Cancer Patients. Clinical Cancer Research, 2008, 14, 5228-5235.	7.0	207
2	Declining Estrogen Receptor-β Expression Defines Malignant Progression of Human Breast Neoplasia. American Journal of Surgical Pathology, 2003, 27, 1502-1512.	3.7	165
3	PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression. Cell Reports, 2017, 21, 3498-3513.	6.4	138
4	The rising incidence of male breast cancer. Breast Cancer Research and Treatment, 2009, 115, 429-430.	2.5	130
5	Breast Cancer Risk in Usual Ductal Hyperplasia Is Defined by Estrogen Receptor-α and Ki-67 Expression. American Journal of Pathology, 2002, 160, 597-604.	3.8	121
6	A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences. Breast Cancer Research and Treatment, 2012, 133, 949-958.	2.5	119
7	Estrogen Receptor \hat{I}^21 Expression Is Regulated by miR-92 in Breast Cancer. Cancer Research, 2010, 70, 4778-4784.	0.9	107
8	Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma. Breast Cancer Research and Treatment, 2010, 121, 555-563.	2.5	60
9	Screenâ€detected pleomorphic lobular carcinoma <i>in situ</i> (PLCIS): risk of concurrent invasive malignancy following a core biopsy diagnosis. Histopathology, 2010, 57, 472-478.	2.9	56
10	Overview of Gynecomastia in the Modern Era and the Leeds Gynaecomastia Investigation Algorithm. Breast Journal, 2011, 17, 246-255.	1.0	55
11	Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects. British Journal of Cancer, 2022, 126, 1125-1139.	6.4	54
12	Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours. Breast, 2013, 22, 13-18.	2.2	52
13	The practicalities of using tissue slices as preclinical organotypic breast cancer models. Journal of Clinical Pathology, 2013, 66, 253-255.	2.0	52
14	Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression – Implications for the practising oncologist. European Journal of Cancer, 2016, 60, 40-48.	2.8	52
15	Characterisation of male breast cancer: a descriptive biomarker study from a large patient series. Scientific Reports, 2017, 7, 45293.	3.3	50
16	Outcome of pure mucoceleâ€like lesions diagnosed on breast core biopsy. Histopathology, 2013, 62, 894-898.	2.9	47
17	A Multi-Centre Investigation Towards Reaching a Consensus on the Immunohistochemical Detection of ERβ in Archival Formalin-ï¬ĸed Paraffin Embedded Human Breast Tissue. Breast Cancer Research and Treatment, 2005, 92, 287-293.	2.5	45
18	Carcinoembryonic Antigen Cell Adhesion Molecule 6 Predicts Breast Cancer Recurrence following Adjuvant Tamoxifen. Clinical Cancer Research, 2008, 14, 405-411.	7.0	44

#	Article	IF	Citations
19	The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example. Journal of Clinical Pathology, 2013, 66, 169-177.	2.0	43
20	Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. Modern Pathology, 2021, 34, 1271-1281.	5.5	43
21	Male breast cancer: an update. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 85-93.	2.8	43
22	Prognostic Significance of Estrogen Receptor Beta in Epithelial Hyperplasia of Usual Type With Known Outcome. American Journal of Surgical Pathology, 2005, 29, 1593-1599.	3.7	36
23	Raman spectroscopy of breast cancer. Applied Spectroscopy Reviews, 2020, 55, 439-475.	6.7	36
24	Phosphorylation of Estrogen Receptor \hat{I}^2 at Serine 105 Is Associated with Good Prognosis in Breast Cancer. American Journal of Pathology, 2010, 177, 1079-1086.	3.8	35
25	The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. Oncotarget, 2016, 7, 43188-43198.	1.8	35
26	Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. Nature Genetics, 2022, 54, 850-860.	21.4	34
27	Differential regulation of oestrogen receptor \hat{l}^2 isoforms by $5\hat{a} \in \hat{l}^2$ untranslated regions in cancer. Journal of Cellular and Molecular Medicine, 2010, 14, 2172-2184.	3.6	30
28	Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation. Breast Cancer Research and Treatment, 2011, 127, 639-648.	2.5	30
29	Observer agreement comparing the use of virtual slides with glass slides in the pathology review component of the POSH breast cancer cohort study. Journal of Clinical Pathology, 2012, 65, 403-408.	2.0	30
30	Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project. British Journal of Cancer, 2021, 124, 1009-1017.	6.4	29
31	Imaging overview of metaplastic carcinomas of the breast: a large study of 71 cases. British Journal of Radiology, 2016, 89, 20140644.	2.2	28
32	Intramammary lymph node metastasis predicts poorer survival in breast cancer patients. Surgical Oncology, 2010, 19, 11-16.	1.6	27
33	Macroscopic handling and reporting of breast cancer specimens pre―and postâ€neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches. Histopathology, 2015, 67, 279-293.	2.9	26
34	Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement. British Journal of Cancer, 2020, 122, 473-482.	6.4	26
35	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. Modern Pathology, 2020, 33, 354-366.	5.5	25
36	The Immune Microenvironment in Breast Carcinoma: Predictive and Prognostic Role in the Neoadjuvant Setting. Pathobiology, 2020, 87, 61-74.	3.8	25

#	Article	IF	Citations
37	Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. Breast Cancer Research and Treatment, 2014, 148, 73-80.	2.5	24
38	IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer. Breast Cancer Research and Treatment, 2017, 166, 527-539.	2.5	24
39	Histological Features and Tissue Microarray Taxonomy of Nigerian Breast Cancer Reveal Predominance of the High-Grade Triple-Negative Phenotype. Pathobiology, 2016, 83, 24-32.	3.8	23
40	Remote Teaching of Histopathology Using Scanned Slides via Skype Between the United Kingdom and Nigeria. Archives of Pathology and Laboratory Medicine, 2017, 141, 298-300.	2.5	23
41	Proline synthesis through PYCR1 is required to support cancer cell proliferation and survival in oxygen-limiting conditions. Cell Reports, 2022, 38, 110320.	6.4	23
42	Prognostic significance of tumour stroma ratio in inflammatory breast cancer. SpringerPlus, 2015, 4, 68.	1.2	21
43	Pleomorphic LCIS what do we know? A UK multicenter audit of pleomorphic lobular carcinoma in situ. Breast, 2018, 38, 120-124.	2.2	21
44	Differential Expression of MicroRNAs in Breast Cancers from Four Different Ethnicities. Pathobiology, 2018, 85, 220-226.	3.8	21
45	The calpain system is associated with survival of breast cancer patients with large but operable inflammatory and non-inflammatory tumours treated with neoadjuvant chemotherapy. Oncotarget, 2016, 7, 47927-47937.	1.8	19
46	Overexpression of cyclins A and B as markers of neoplastic glandular lesions of the cervix. Gynecologic Oncology, 2004, 92, 628-634.	1.4	18
47	A Case-Matched Gender Comparison Transcriptomic Screen Identifies elF4E and elF5 as Potential Prognostic Markers in Male Breast Cancer. Clinical Cancer Research, 2017, 23, 2575-2583.	7.0	16
48	Differential expression of cyclin-dependent kinase inhibitors and apoptosis-related proteins in endocervical lesions. European Journal of Cancer, 2007, 43, 2011-2018.	2.8	14
49	Palpable Ductal Carcinoma in Situ: Analysis of Radiological and Histological Features of a Large Series With 5-Year Follow-Up. Clinical Breast Cancer, 2013, 13, 486-491.	2.4	14
50	An unusual case of a large fibroepithelial stromal polyp presenting as a nipple mass. BMC Research Notes, 2013, 6, 345.	1.4	14
51	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. Scientific Reports, 2017, 7, 8078.	3.3	14
52	Management of B3 Lesionsâ€"Practical Issues. Current Breast Cancer Reports, 2019, 11, 83-88.	1.0	14
53	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. Modern Pathology, 2021, 34, 2130-2140.	5.5	14
54	Breast Cancer Reporting in Lagos, Nigeria: Implications for Training and Education in Africa. Journal of Global Oncology, 2016, 2, 397-402.	0.5	13

#	Article	IF	CITATIONS
55	Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncology, The, 2021, 22, e435-e445.	10.7	13
56	What is the significance of flat epithelial atypia and what are the management implications?. Journal of Clinical Pathology, 2011, 64, 1001-1004.	2.0	12
57	Radiological and Pathological Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Brief Literature Review. Pathobiology, 2015, 82, 124-132.	3.8	12
58	Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer. Journal of Pathology: Clinical Research, 2018, 4, 241-249.	3.0	12
59	Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study. Breast, 2022, 61, 145-155.	2.2	12
60	The important role of the histopathologist in clinical trials: challenges and approaches to tackle them. Histopathology, 2020, 76, 942-949.	2.9	11
61	Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer. Molecular Cancer Therapeutics, 2020, 19, 945-955.	4.1	11
62	Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patientsÂundergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2) Tj	ET@qФ 0 0	rg BT /Overlo
63	Risk for Subsequent Development of Breast Cancer. American Journal of Surgical Pathology, 2003, 27, 271-274.	3.7	11
64	Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer. Journal of Cellular Physiology, 2017, 232, 2246-2252.	4.1	9
65	Problems (and solutions) in the study of male breast cancer. Rare Tumors, 2010, 2, 78-78.	0.6	8
66	Pleomorphic lobular carcinoma in situ. Diagnostic Histopathology, 2012, 18, 119-123.	0.4	8
67	Extramedullary Haematopoiesis in Axillary Lymph Nodes of Breast Carcinoma Patients Receiving Neoadjuvant Chemotherapy: A Potential Diagnostic Pitfall. Pathobiology, 2019, 86, 167-172.	3.8	8
68	Clinical Importance of Estrogen Receptor \hat{I}^2 Isoforms in Breast Cancer. Journal of Clinical Oncology, 2008, 26, 5825-5825.	1.6	7
69	Pathology of the male breast. Diagnostic Histopathology, 2019, 25, 138-142.	0.4	7
70	Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. Clinical Cancer Research, 2022, 28, 1323-1334.	7.0	7
71	Receptor Status after Neoadjuvant Therapy of Breast Cancer: Significance and Implications. Pathobiology, 2022, 89, 297-308.	3.8	7
72	Hormone receptors in defining breast cancer prognosisâ€"time for a rethink?. Nature Clinical Practice Oncology, 2007, 4, 204-205.	4.3	6

#	Article	IF	CITATIONS
73	Breast Neoplasms with Dermal Analogue Differentiation (Mammary Cylindroma): Report of 3 Cases and a Proposal for a New Terminology. Pathobiology, 2015, 82, 172-178.	3.8	6
74	HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes. Scientific Reports, 2016, 6, 35121.	3.3	6
75	Why is LCIS Importantâ€"Pathological Review. Current Breast Cancer Reports, 2021, 13, 132-140.	1.0	6
76	Re: Skliriset al. Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue.J Pathol 2002;196: 155-162. Journal of Pathology, 2003, 199, 130-130.	4. 5	5
77	Intraductal papilloma in an axillary lymph node of a patient with human immunodeficiency virus: a case report and review of the literature. Journal of Medical Case Reports, 2014, 8, 162.	0.8	5
78	Heterogeneity of germline variants in high risk breast and ovarian cancer susceptibility genes in India. Precision Clinical Medicine, 2018, 1, 75-87.	3.3	5
79	Histopathology during the COVID-19 pandemic: resilience through adaptation and innovation. Diagnostic Histopathology, 2021, 27, 108-115.	0.4	5
80	Morphological and molecular changes following neoadjuvant endocrine therapy of oestrogen receptorâ€positive breast cancer: implications for clinical practice. Histopathology, 2021, 79, 47-56.	2.9	5
81	Elucidating the chemical and structural composition of breast cancer using Raman micro-spectroscopy. EXCLI Journal, 2021, 20, 1118-1132.	0.7	5
82	Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study. British Journal of Surgery, 2022, 109, 800-803.	0.3	5
83	The Estrogen Receptors \hat{l}_{\pm} , \hat{l}_{-}^2 , and \hat{l}_{-}^2 cx. Clinical Cancer Research, 2005, 11 , 8222-8223.	7.0	4
84	Radiation-Associated Primary Osteosarcoma of the Breast. Pathobiology, 2020, 87, 322-326.	3.8	4
85	Recommendations for cellular and molecular pathology input into clinical trials: a systematic review and metaâ€aggregation. Journal of Pathology: Clinical Research, 2021, 7, 191-202.	3.0	4
86	Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERl^{1}_{\pm} -positive breast cancer. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 355-371.	0.8	4
87	Breast screening atypia and subsequent development of cancer: protocol for an observational analysis of the Sloane database in England (Sloane atypia cohort study). BMJ Open, 2022, 12, e058050.	1.9	4
88	Characterization of the Immune Microenvironment in Inflammatory Breast Cancer Using Multiplex Immunofluorescence. Pathobiology, 2023, 90, 31-43.	3.8	4
89	In situ lobular proliferations of the breast. Diagnostic Histopathology, 2018, 24, 58-63.	0.4	3
90	Metaplastic Breast Cancer Masquerading as Liposarcoma of the Breast: A Case Report following Oncoplastic Treatment. Pathobiology, 2018, 85, 261-265.	3.8	3

#	Article	IF	CITATIONS
91	Unusual Presentation of Mammary Calciphylaxis in a Patient on Long-Standing Renal Dialysis. Pathobiology, 2020, 87, 317-321.	3.8	3
92	Diagnostic pitfalls in needle core biopsy of the breast. Diagnostic Histopathology, 2022, 28, 156-160.	0.4	3
93	Investigating and critically appraising the expression and potential role of androgen receptor in breast carcinoma. Hormone Molecular Biology and Clinical Investigation, 2011, 7, 273-8.	0.7	2
94	Bilateral Neurofibromas of the Nipple-Areolar Complex: A Case Report and Approach to Diagnosis. Case Reports in Pathology, 2018, 2018, 1-5.	0.3	2
95	Rare morphological appearance of breast carcinoma. Journal of Clinical Pathology, 2019, 72, 90-90.	2.0	2
96	Reply to "Comment on: Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project― British Journal of Cancer, 2021, 124, 1463-1464.	6.4	2
97	Estrogen receptor β—which one and where should we draw the line?. Human Pathology, 2006, 37, 498-498.	2.0	1
98	Tailoring Therapy for Locally Advanced Breast Cancer Using Molecular Profiles. Drugs, 2011, 71, 1947-1955.	10.9	1
99	A rare and unusual cause of mammographic calcification in the breast. Journal of Clinical Pathology, 2017, 70, 89-89.	2.0	1
100	Metastatic "Ductal Carcinoma In Situ–Like―Lobular Carcinoma in a Lymph Node: A Case Report and Review of the Literature. International Journal of Surgical Pathology, 2020, 28, 436-439.	0.8	1
101	Impact of COVID-19 on the practice of breast pathologists: a survey of breast pathologists in the UK and Ireland. Journal of Clinical Pathology, 2023, 76, 234-238.	2.0	1
102	Assessment of clinical trial protocols for pathology content using the <scp>SPIRITâ€Path</scp> guidelines highlights areas for improvement. Journal of Pathology: Clinical Research, 0, , .	3.0	1
103	Role of ERβ in Clinical Breast Cancer. Cancer Treatment and Research, 2009, 147, 1-20.	0.5	0
104	Breast Translational Research: Past, Present and Future. Pathobiology, 2015, 82, 111-112.	3.8	0
105	Male Breast Lesions. , 2017, , 265-274.		0
106	Pathology of High-Risk Breast Lesions. , 2018, , 103-114.		0
107	Gene Expression of $\mathrm{ER}\hat{l}^2$ Isoforms in Laser Microdissected Human Breast Cancers: Implications for Gene Expression Analyses. Analytical Cellular Pathology, 2009, 31, 467-473.	1.4	0
108	Lobular Neoplasia. , 2017, , 77-86.		0

#	Article	IF	CITATIONS
109	Breast Cancer in Sub-Saharan Africa. , 2017, , 81-93.		0
110	Hormone Receptors in Breast Cancer. Encyclopedia of Pathology, 2018, , 1-5.	0.0	0
111	Male Breast Cancer. Encyclopedia of Pathology, 2018, , 1-6.	0.0	0
112	Hormone Receptors in Breast Cancer. Encyclopedia of Pathology, 2020, , 161-165.	0.0	0
113	Male Breast Cancer. Encyclopedia of Pathology, 2020, , 263-268.	0.0	0
114	Abstract P3-12-36: The diagnosis and prognosis of ductal carcinoma in situ (DCIS) with microinvasion - Results from the United Kingdom Sloane project. Cancer Research, 2022, 82, P3-12-36-P3-12-36.	0.9	0
115	Abstract P1-22-01: Predictors of inaccurate pre-operative size assessment of screen detected DCIS and impact on recurrence rates. Cancer Research, 2022, 82, P1-22-01-P1-22-01.	0.9	0
116	Abstract P1-22-06: A longitudinal cohort study of outcomes in 311 women with unresected ductal carcinoma in situ detected through the English breast screening programme. Cancer Research, 2022, 82, P1-22-06-P1-22-06.	0.9	0
117	Abstract P2-13-08: Combined peri-operative lapatinib and trastuzumab in early HER2-positive breast cancer - Long term results of the randomized UK EPHOS-B trial. Cancer Research, 2022, 82, P2-13-08-P2-13-08.	0.9	0
118	Morphological Features and Immunohistochemical Profiling of Male Breast Gynaecomastia; A Large Tissue Microarray Study. Frontiers in Oncology, 0, 12, .	2.8	0